Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DYAX
- CUSIP: 26746E10
- Web: N/A
Average Prices:- 50 Day Moving Avg: $37.73
- 200 Day Moving Avg: $29.05
- 52 Week Range: $14.06 - $38.56
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -274.36
- P/E Growth: 0.00
Misc:- Average Volume: 3.62 million shs.
Frequently Asked Questions for Dyax Corp. (NASDAQ:DYAX)
What is Dyax Corp.'s stock symbol?
Dyax Corp. trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax Corp.'s earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) issued its earnings results on Wednesday, October, 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). The business had revenue of $24.70 million for the quarter, compared to analysts' expectations of $24.96 million. The company's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the business earned ($0.01) EPS. View Dyax Corp.'s Earnings History.
Who are some of Dyax Corp.'s key competitors?
Some companies that are related to Dyax Corp. include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy Dyax Corp. stock?
Shares of Dyax Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Dyax Corp. stock cost?
One share of Dyax Corp. stock can currently be purchased for approximately $38.41.
Earnings History for Dyax Corp. (NASDAQ:DYAX)Earnings History by Quarter for Dyax Corp. (NASDAQ:DYAX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/28/2015 | Q315 | ($0.08) | ($0.08) | $24.96 million | $24.70 million | View | N/A |  |
| 7/29/2015 | Q215 | ($0.04) | ($0.06) | $23.40 million | $264.00 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.05) | ($0.05) | $21.79 million | $20.40 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.04) | ($0.02) | $19.90 million | $26.00 million | View | N/A | |
| 10/28/2014 | Q314 | ($0.06) | ($0.01) | $15.70 million | $22.00 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.05) | ($0.02) | $14.13 million | $19.59 million | View | N/A | |
| 4/30/2014 | Q1 2014 | ($0.05) | ($0.05) | $13.65 million | $14.12 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.04) | ($0.02) | $15.84 million | $16.90 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS
Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Dyax Corp. (NASDAQ:DYAX)Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/10/2015 | Thomas L Kempner | Director | Sell | 6,000 | $22.47 | $134,820.00 | |
| 8/28/2015 | Thomas L Kempner | Director | Sell | 17,947 | $23.83 | $427,677.01 | |
| 8/18/2015 | Thomas L Kempner | Director | Sell | 18,035 | $23.83 | $429,774.05 | |
| 8/13/2015 | Thomas L Kempner | Director | Sell | 4,848 | $23.81 | $115,430.88 | |
| 7/20/2015 | Henry E Blair | Director | Sell | 50,000 | $27.05 | $1,352,500.00 | |
| 6/8/2015 | David J Mclachlan | Director | Sell | 75,000 | $25.63 | $1,922,250.00 | |
| 3/6/2015 | Andrew D Ashe | EVP | Sell | 2,400 | $15.50 | $37,200.00 | |
| 3/5/2015 | Burt A Adelman | CMO | Sell | 9,375 | $15.66 | $146,812.50 | |
| 3/5/2015 | George V Migausky | CFO | Sell | 5,000 | $15.86 | $79,300.00 | |
| 3/5/2015 | Gustav Christensen | CEO | Sell | 6,250 | $15.86 | $99,125.00 | |
| 2/26/2015 | Andrew D Ashe | EVP | Sell | 1,500 | $15.34 | $23,010.00 | |
| 1/2/2015 | Burt A Adelman | CMO | Sell | 75,000 | $14.05 | $1,053,750.00 | |
| 12/5/2014 | Thomas L Kempner | Director | Sell | 14,764 | $13.79 | $203,595.56 | |
| 11/21/2014 | Thomas L Kempner | Director | Sell | 100,000 | $13.20 | $1,320,000.00 | |
| 9/12/2014 | Thomas L Kempner | Director | Sell | 12,400 | $11.00 | $136,400.00 | |
| 8/26/2014 | Thomas L Kempner | Director | Sell | 37,000 | $10.39 | $384,430.00 | |
| 8/19/2014 | Thomas L Kempner | Director | Sell | 113,755 | $9.67 | $1,100,010.85 | |
| 8/7/2014 | Thomas L Kempner | Director | Sell | 33,190 | $9.25 | $307,007.50 | |
| 6/13/2014 | George V Migausky | CFO | Sell | 16,000 | $8.26 | $132,160.00 | |
| 3/5/2014 | Henry Blair | Director | Sell | 150,000 | $10.46 | $1,569,000.00 | |
| 3/3/2014 | Andrew Ashe | EVP | Sell | 30,000 | $10.00 | $300,000.00 | |
| 3/3/2014 | Burt Adelman | CMO | Sell | 55,000 | $9.68 | $532,400.00 | |
| 2/26/2014 | Andrew Ashe | VP | Sell | 2,723 | $10.10 | $27,502.30 | |
| 12/5/2013 | Thomas Kempner | Director | Sell | 400,000 | $8.37 | $3,348,000.00 | |
| 8/13/2013 | Andrew Ashe | VP | Sell | 32,500 | $4.30 | $139,750.00 | |
| 5/16/2013 | Marc D Kozin | Director | Buy | 22,971 | $2.46 | $56,508.66 | |
| 2/25/2013 | George V Migausky | CFO | Sell | 4,275 | $3.28 | $14,022.00 | |
| 2/25/2013 | Ivana Magovcevic | COO | Sell | 4,015 | $3.24 | $13,008.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dyax Corp. (NASDAQ:DYAX)
Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
| Source: |
|
Dyax Corp. (DYAX) Chart for Wednesday, May, 24, 2017
